Expert Review of Pharmacoeconomics & Outcomes Research

• Clinical and Economic Consequences of Pharmacogenetic Dosing of Warfarin How cost-effective is warfarin dosing using patient pharmacogenetics?
  Expert Review of Pharmacoeconomics & Outcomes Research, September 17, 2010
• Impact of MDR Pseudomonas aeruginosa Infection on Patient Outcomes What is the morbidity, mortality, and economic impact associated with multidrug-resistant P. aeruginosa?
  Expert Review of Pharmacoeconomics & Outcomes Research, August 10, 2010
• Preventing Surgical Site Infections After Bariatric Surgery As obesity is a risk factor for surgical site infections in general, what other risk factors are associated with bariatric surgery?
  Expert Review of Pharmacoeconomics & Outcomes Research, July 15, 2010
• The Economics of Improved Cancer Survival Rates Are gains in cancer diagnosis and treatment worth the increased costs?
  Expert Review of Pharmacoeconomics & Outcomes Research, June 01, 2010
• Patient Outcomes After Anti TNF-Alpha Drugs for Crohn's Disease What are the potential benefits and dangers of switching from one anti TNF-alpha agent to another?
  Expert Review of Pharmacoeconomics & Outcomes Research, May 03, 2010
• Cancer Prevention: Major Initiatives and Looking Into the Future At least half of cancers are preventable. What prevention initiatives are currently underway?
  Expert Review of Pharmacoeconomics & Outcomes Research, April 01, 2010
• Long-Term Outcomes in Patients Undergoing PCI With Drug-Eluting Stents Do drug-eluting stents improve long-term rates of death and MI in PCI?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 26, 2010
• Is Oseltamivir Safe? Is oseltamivir use associated with increased risk of abnormal behaviors and sudden death?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 01, 2010
• Are Intensive Lipid-Lowering Regimens an Optimal Economic Strategy for ACS? How do intensive lipid-lowering regimens compare with generic low-dose statins for ACS?
  Expert Review of Pharmacoeconomics & Outcomes Research, December 02, 2009
• Outcomes of Self-Help Efforts in Anxiety Disorders Anxiety disorders are very prevalent in our society. How effective are patients when they try to help themselves?
  Expert Review of Pharmacoeconomics & Outcomes Research, November 10, 2009
• Burden of Skin Diseases Out of 3000 known skin diseases, Psoriasis alone affects millions of people worldwide. Read this clinical update to find out how these diseases can impact health status and quality of life.
  Expert Review of Pharmacoeconomics & Outcomes Research, June 01, 2009
• Estimating the Clinical and Economic Benefits of Smoking Cessation From a short-term perspective, how cost-effective are smoking cessation products?
  Expert Review of Pharmacoeconomics & Outcomes Research, June 01, 2009
• Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Quality of Life How serious can premenstrual syndrome get and what can we do to treat it?
  Expert Review of Pharmacoeconomics & Outcomes Research, April 01, 2009
• Use of Patient Data to Improve Outcomes: Narcotics for Noncancer Pain Read this clinical update to learn about strategies that investigators use to gain information on narcotic use for chronic noncancer pain.
  Expert Review of Pharmacoeconomics & Outcomes Research, April 01, 2009
• Sleep Disorders: Impact on Daytime Functioning and Quality of Life How do some of the most common sleep disorders affect general health and quality of life?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 01, 2009
• Are the Economics of Complementary Medicine Different to Conventional? How do the cost, outcome and policy implications of complementary and alternative medicine use compare to conventional therapies?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 01, 2009
• Generic Olanzapine: Health Authority Opportunity or Nightmare? Do recent formulations of Olanzapine lead to more relapses for patients with schizophrenia?
  Expert Review of Pharmacoeconomics & Outcomes Research, December 01, 2008
• Prevention and Treatment of Influenza Using Antiviral Drugs Based on Cost-Effectiveness A detailed look at four antiviral drugs available for the prevention and treatment of influenza infections.
  Expert Review of Pharmacoeconomics & Outcomes Research, December 01, 2008
• Addressing the Needs of Cancer Survivors: Issues and Challenges A substantial minority of cancer survivors experience long-term physical, social and economic consequences. What services are available to them, and how can their quality of life be improved?
  Expert Review of Pharmacoeconomics & Outcomes Research, October 01, 2008
• Impact of Patient Sample on Costs of Events in Pharmacoeconomic Models Pharmacoeconomic guidelines have centered on improving the measurement of effectiveness, but have ignored the assessment of cost inputs.
  Expert Review of Pharmacoeconomics & Outcomes Research, October 01, 2008